Skip to main content
  • Home
  • ADVANCES IN IMAGING: OPTIMISING MR AND CT IN DAILY PRACTICE

ADVANCES IN IMAGING: OPTIMISING MR AND CT IN DAILY PRACTICE

Topic:
  • Prevention

Available Credit:

  • 2.00 EBAC

Course Published On:

Course Expiry Date:

Overview

Currently, despite guidelines acknowledging the utility of imaging for pre-procedural planning, specific guidance is lacking.
 

This faculty-led, educational series has been devised, in conjunction with course director Dr Andrew Arai, to address that need and to provide practical guidance for pre-procedural imaging during the planning phases of atherosclerosis and ventricular arrythmia management.
 

For both disease states we provide a broad overview of the use of imaging through peer-to-peer discussion with therapy area experts; specific imaging applications are explored through faculty presented case reviews.

Disclosure

In compliance with ACCREDITED (EBAC / EACCME / ISCP) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. 

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. 

 

This programme is supported by an unrestricted educational grant from Circle Cardiovascular Imaging. The scientific programme has not been influenced in any way by the sponsor.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable. 

 

The session, ‘Advances In Imaging: Optimising MR and CT in Daily Practice’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 2 hours of external CME credits. 

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). 

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instructions to Participants

There is no fee for taking part in this online learning activity. 

 

Activities are designed to be completed within 2 hours and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame. 

 

To complete the course and claim certification participants must: 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions. 

  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

This programme is intended to educate:

  • Electrophysiologists, Imaging Specialists, Cardiologists and Interventional Cardiologists.

Learning Objectives

The overall programme, 'Advances In Imaging: Optimising MR and CT in Daily Practice' endeavours to best address the following learning objectives:

  • Interpret existing clinical and meta data for use of pre-procedural, image-aided ablation in ventricular arrhythmias
  • Identify where pre-procedural imaging may complement the current ablation workflow in ventricular arrhythmias
  • Recall the clinical benefits of quantitative, MRI-based approaches to evaluate ischaemia
  • Apply quantitative CMR imaging to complement existing procedural workflows in revascularisation procedures
Register now Log in

Module

Title

Duration

Speakers

Ventricular Arrhythmias and Ablation Pre-procedural imaging in ventricular arrhythmias: A peer-to-peer discussion 29mins 9 seconds Antonio Berruezo (Barcelona, Spain) Saman Nazarian (Philadelphia, USA)
Ventricular Arrhythmias and Ablation Pre-Procedural Planning in VT Post-MI: Case review 18mins 55seconds Saman Nazarian (Philadelphia, USA)
Quantitative CMR: A Case Review of its Diagnostic Utility in CAD Case 1: A 54 year old with exertional angina; two risk factors for CAD 11mins 38seconds Andrew Arai (Bethesda, USA)
Quantitative CMR: A Case Review of its Diagnostic Utility in CAD Cases 2 and 3: A 42 year old healthy volunteer; no family history or risk factors for CAD, and a 68 year old male with history of atypical chest discomfort; one risk factor for CAD 6mins 48seconds Andrew Arai (Bethesda, USA)
Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST Introduction and Learning Objectives 2mins 10seconds Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)
Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST What does the Literature Say? 8mins 32seconds Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)
Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST Qualitative or Quantitative? 8mins 44seconds Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)
Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST AI and its Impact on CMR 8mins 16seconds Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)
Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST International Guidelines – What Do They Say? 5mins 35seconds Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)
Ventricular Arrhythmias and Ablation.

Pre-procedural imaging in ventricular arrhythmias: A peer-to-peer discussion

Duration: 29mins 9 seconds

Speakers: Antonio Berruezo (Barcelona, Spain) Saman Nazarian (Philadelphia, USA)

Ventricular Arrhythmias and Ablation.

Pre-Procedural Planning in VT Post-MI: Case review

Duration: 18mins 55seconds

Speakers: Saman Nazarian (Philadelphia, USA)

Quantitative CMR: A Case Review of its Diagnostic Utility in CAD.

Case 1: A 54 year old with exertional angina; two risk factors for CAD

Duration: 11mins 38seconds

Speakers: Andrew Arai (Bethesda, USA)

Quantitative CMR: A Case Review of its Diagnostic Utility in CAD.

Cases 2 and 3: A 42 year old healthy volunteer; no family history or risk factors for CAD, and a 68 year old male with history of atypical chest discomfort; one risk factor for CAD

Duration: 6mins 48seconds

Speakers: Andrew Arai (Bethesda, USA)

Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST.

Introduction and Learning Objectives

Duration: 2mins 10seconds

Speakers: Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)

Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST.

What does the Literature Say?

Duration: 8mins 32seconds

Speakers: Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)

Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST.

Qualitative or Quantitative?

Duration: 8mins 44seconds

Speakers: Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)

Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST.

AI and its Impact on CMR

Duration: 8mins 16seconds

Speakers: Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)

Looking to the Future: Quantitative vs Qualitative Myocardial Perfusion PODCAST.

International Guidelines – What Do They Say?

Duration: 5mins 35seconds

Speakers: Andrew Arai (Bethesda, USA) Chiara Bucciarelli-Ducci (London, UK)

Course Director

Andrew Arai

Dr Andrew Arai is a consultant in cardiovascular magnetic resonance imaging and a Past President of the Society for Cardiovascular Magnetic Resonance.

View full profile

Speaker

Antonio Berruezo

Teknon Medical Center, Barcelona, Spain

Dr Berruezo is Head of the Arrhythmia Department and Director or Research and Innovation at the Heart Institute, Teknon Medical Center, part of the Quironsalud Hospitals Group in Barcelona, Spain and also Director of the International Fellow’s Program at the Center's Arrhythmia Department.

View full profile

Saman Nazarian

University of Pennsylvania Perelman School of Medicine

Dr Nazarian obtained a Doctorate in Medicine from Stanford University and PhD in Clinical Epidemiology from the Johns Hopkins Bloomberg School of Public Health.

View full profile

2.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Imaging vs Angiography-led PCI: An Overview for DES Implantation
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging vs angiography-led PCI: What does success look like?
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging-based Procedure-planning with OCT: Application to Clinical Practice
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Dual antiplatelet therapy for acute stroke and TIA
  • 1.00 EBAC

Learning objectives

  • To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
  • To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
  • To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more